Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) can be a lethal complication seen after stem cell transplantation. The typical pathological features of TA-TMA are arteriole endothelium injury and intra-arteriole thrombosis, whereas the clinical features include hemolytic anemia, exhausting thrombocytopenia and microangiopathyinduced organ damage. 1, 2 Endothelial injury as a result of the conditioning regimen, total body irradiation, immunosuppressants, infection and GvHD is thought to contribute to the pathogenesis of TA-TMA. [2] [3] [4] According to recent relatively largescale cohort studies, TA-TMA occurs in 10-25% of patients, 3 with a reported mortality rate ranging from 60 to 90%. [5] [6] [7] In addition to TA-TMA, hepatic veno-occlusive disease (VOD) is a complication that occurs after hematopoietic stem cell transplantation (HSCT) as a result of endothelial injury. Both TA-TMA and hepatic VOD finally lead to multiorgan failure. The differences between the clinical symptoms of TA-TMA and hepatic VOD are thought to be related to which organs are affected and which parts of the vessels are injured. 8, 9 Although there is no established treatment for hepatic VOD, some studies have reported that low-dose heparin prevents the development of hepatic VOD. 10, 11 Dalteparin is a type of low molecular weight heparin that is associated with a lower frequency of bleeding complications and is widely used in Japan to prevent the development of hepatic VOD. Danaparoid is a heparin-like protein with a long half-life that exhibits much higher specificity for Factor Xa than low molecular weight heparin. One retrospective study suggested that danaparoid may be a promising candidate for the prophylaxis of VOD after allogeneic HSCT. 12 These findings also suggest that danaparoid may be an appropriate drug for the prevention of TA-TMA, in addition to VOD. However, few studies have assessed danaparoid as a prophylactic against TA-TMA after HSCT.
Data from a total of 223 consecutive patients who received allogeneic HSCT for hematological disease at Tokai University Hospital from January 2004 to January 2013 were analyzed retrospectively in the present study. The cohort included 24 patients undergoing a second or more transplantation. For VOD prophylaxis, until March 2008, patients were given dalteparin (3000 IU/24 h continuous iv infusion, from Day 1 to Day 28), whereas from April 2008, patients were given danaparoid (1250 IU, bid, from Day 1 to Day 28). The present study was performed in accordance with the ethics standards of Tokai University School of Medicine. The diagnosis of TA-TMA was based on nine criteria (six laboratory, three clinical), as reported previously. 3, 13 The severity of TA-TMA was assessed using Common Toxicity Criteria for Bone and Marrow Transplant Thrombotic Microangiopathy. 5 Of the 223 patients included in the study, 26.5% (n = 59) were administered dalteparin and 73.5% (n = 164) danaparoid. Baseline patient characteristics are summarized in Table 1 . The clinical features of the patients with TA-TMA are given in Supplementary Table 1 (Supplementary information is available at Bone Marrow Transplantation's website). In univariate analysis, the statistically significant factors related to the development of TA-TMA were VOD prophylaxis with danaparoid, lymphoid malignancy, a past history of HSCT and disease risk ( Table 2 ). Multivariate analysis using the Fine and Gray model included significant factors related to the development of TA-TMA, as identified in univariate analysis, as well as unrelated donor, which was moderately associated with TA-TMA (P = 0.08). Multivariate analysis identified VOD prophylaxis with danaparoid, lymphoid malignancy, past history of HSCT and disease risk as significant factors affecting the development of TA-TMA (Table 2 ).
In patients classified as having standard disease risk, the incidence of TA-TMA in the dalteparin cohort was 17.1% (95% CI 6.8-31.4%), compared with 4.6% (95% CI 1.7-9.8%; P = 0.02; Supplementary Figure 1a1 ) in the danaparoid cohort. However, in patients classified as being at high risk of disease, there was no significant difference between the dalteparin and danaparoid cohorts (29.2% (95% CI 12.5-48.1%) vs 21.8% (95% CI 12.0-33.5%), respectively; P = 0.58; Supplementary Figure 1a2) . Among patients undergoing their first HSCT, the incidence of developing TA-TMA was significantly lower in the danaparoid than dalteparin cohort (7.0% (95% CI 3.6-12.0%) vs 20.0% (95% CI 10.6-31.5%), respectively; P = 0.01; Supplementary Figure 1b1) . However, there was no significant difference between the dalteparin and danaparoid cohorts for patients who had undergone HSCT previously (50.0% (95% CI 0.2-92.7%) vs 35.0% (95% CI 15.1-55.8%), respectively; P = 0.61; Supplementary Figure 1b2 ). Among patients with lymphoid malignancy, the frequency of developing TA-TMA was significantly lower in the danaparoid than dalteparin cohort (12.5% (95% CI 5.4-22.6%) vs 40.0% (95% CI 20.7-58.7%), respectively; P = 0.01; Supplementary Figure 1c) . The incidence of hepatic VOD did not differ significantly between the dalteparin and danaparoid cohorts.
Overall survival (OS) was significantly lower in the dalteparin than danaparoid cohort (49.3% (95% CI 35.7-61.6%) vs 65.2% (95% CI 56.7-72.5%), respectively; P = 0.03). Moreover, the incidence of non-relapse mortality (NRM) within 100 days after HSCT was significantly lower in the danaparoid than dalteparin cohort (8.6% (95% CI 4.9-13.5%) vs 20.3% (95% CI 11.2-31.5%), respectively; P = 0.02; Supplementary Figure 2) . Hemorrhagic events rated greater than Grade 3 were observed in four patients in the dalteparin cohort (intra-cranial n = 3; lung n = 1) and in six patients in the danaparoid cohort (intra-cranial n = 2; lung n = 1; intestinal n = 3). The difference between the two groups was not significant (P = 0.32). Three patients in the dalteparin cohort and two in the danaparoid cohort died from bleeding. Only one patient in the dalteparin cohort developed heparin-induced thrombocytopenia (HIT).
In the present study, the findings of univariate and multivariate analysis revealed that danaparoid has more favorable effects in preventing TA-TMA than dalteparin. Particularly among patients considered to be at standard disease risk, the effect was remarkable. There were some differences in patient characteristics between the dalteparin and danaparoid cohorts, and one of the reasons for this seems to be the fact that each type of VOD prophylaxis was used in different generations (dalteparin used from January 2004 to March 2008; danaparoid used from April 2008 to January 2013). Indeed, there were significant differences in patient age, conditioning regimen, cord blood as a source of stem cells and tacrolimus use between the two groups. To confirm the benefit of danaparoid, these differences between the groups were the limitations of this study. However, these factors did not reach statistical significance for an association with the development of TA-TMA in univariate analysis. Among the factors that differed significantly between the two cohorts, only lymphoid malignancy was found to be significantly associated with the development of TA-TMA in both univariate and multivariate analyses. This indicates that lymphoid malignancy is an independent risk factor for TA-TMA. However, danaparoid reduced the frequency of TA-TMA compared with dalteparin, even in patients with lymphoid malignancy (Supplementary Figure 1c) .
As indicated in Table 2 , lymphoid malignancy, high-risk disease status and a previous history of allogeneic HSCT are factors affecting the occurrence of TA-TMA, as determined by either univariate or multivariate analysis. These factors are associated with a history of multiple chemotherapies, which induce endothelial injury. In particular, among patients who had the risk factors of high-risk disease status and a history of allogeneic HSCT, the cumulative incidence of TA-TMA was same in the danaparoid and dalteparin cohorts. It seems that the beneficial effect of danaparoid in preventing the development of TA-TMA is limited among high-risk patients.
In the present study, there were fewer bleeding events in the danaparoid cohort, although the difference failed to reach statistical significance. Some studies have reported that danaparoid can control HIT, 14, 15 and, in the present study, HIT did not develop in the danaparoid cohort. We hypothesize that danaparoid prevents the development of TA-TMA because it has both an anti-inflammatory effect and decreases bleeding events in the microvasculature. Recently, some studies have reported successful treatment of TA-TMA with recombinant human soluble thrombomodulin, rituximab and daclizumab. Moreover, previous studies reported that either the classical or alternative complement pathway dysregulation is involved in the pathogenesis of TA-TMA. 16 The complement inhibitor eculizumab may be a therapeutic option for TA-TMA not only in children but also in adults. 17, 18 Abbreviations: ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; ATLL = adult T cell leukemia/lymphoma; BU = busulfan; CML = chronic myelogenous leukemia; CSA = cyclosporine A; Cy = cyclophosphamide; FLU = fludarabine; GvHD = graft-versus-host disease; HCT = hematopoietic stem cell transplantation; L-PAM = melphalan; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; ML = malignant lymphoma; MM = multiple myeloma; MTX = methotrexate; RIC = reduced intensity conditioning; SSA = severe aplastic anemia; TBI = total body irradiation. Disease risk status categories: low risk, all diseases in first or second complete remission, CML in chronic phase, all MDS, all SAA; high risk, all diseases in relapse, progressive disease, ⫺ third complete remission, CML in accelerated phase or blast crisis. Danaparoid cohort was the trial cohort, and dalteparin cohort was the historical control. 
